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Background: Genes that have been subject to adaptive evolution can produce varying degrees of pathology or
differing symptomatology. ErbB family receptor activation will initiate a number of downstream signaling
pathways, such as mitogen-activated protein kinase (MAPK), activator of transcription (STAT), the modula-
tion of calcium channels, and so on, all of which lead to aggressive tumor behavior. However, the evolution-
ary mechanisms operating in the retention of ErbB family genes and the changes in selection pressures are
not clear.
Results: Sixty-two full-length cDNA sequences from 27 vertebrate species were extracted from the UniProt
protein database, NCBI's GenBank and the Ensembl database. The result of phylogenetic analysis showed
that the four ErbB family members in vertebrates might be formed by gene duplication. In order to determine
the mode of evolution in vertebrates, selection analysis and functional divergence analysis were combined to
explain the relationship of the site-speciﬁc evolution and functional divergence in the vertebrate ErbB family.
Our results indicate that the acceleration of asymmetric evolutionary rates and purifying selection together
were the main force for the production of ErbBs, and positive selections were detected in the ErbB family.
Conclusion: An evolutional phylogeny of 27 vertebrates was presented in our study; the tree showed that the
genes have evolved through duplications followed by purifying selection, except for seven sites, which
evolved by positive selection. There was one common site with positive selection and functional divergence.
In the process of functional differentiation evolving through gene duplication, relaxed selection may play an
important part.© 2013 Elsevier Inc. All rights reserved.1. Background
Different related species such as humans and chimpanzees often
experience the same medical conditions with varying symptomatolo-
gy or prevalence, suggesting that genetic disease can occur as a
by-product of an adaption which confers a large selective advantagef Guangxi Medical University,
enwu_he@126.com (W. He),
(F. Pang), xianlei59@163.com
@sina.com (Y. Wu),
rights reserved.[1]. Cancer, known medically as a malignant neoplasm, is the result
of the proliferation of misregulated cells. Merlo et al. [2] showed
that cancer is an evolutionary and ecological process, while Weinberg
[3] speculated that the genes which cause cancer are ancient and
highly conserved. The genes of cellular cooperation that evolved
with multicellularity about a billion years ago are the same genes
that malfunction to cause cancer [4]. Therefore, comparative evolu-
tionary genomics can offer insights into these disease mechanisms
by correlating molecular differences between species, and clarifying
disease-causative genes and pathways.
There are four ErbB family members in vertebrates: ErbB1/EGFR,
ErbB2/neu/HER2, ErbB3/HER3, and ErbB4/HER4. ErbB receptors con-
tain three domains: an extracellular region or ectodomain that in-
cludes 620 amino acids, a single transmembrane-spanning region,
and a cytoplasmic tyrosine kinase domain. The extracellular region
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and CR2, where L denotes a leucine-rich repeat domain and CR a
cysteine-rich region [5].
All ErbB family members except ErbB3 are associated with tyrosine
kinase activity. The ErbB family members exist as monomers spanning
the plasma membrane of the cell. ErbB family proteins were dimerized
by receptor homo-dimerization or hetero-dimerization, and subse-
quently activate tyrosine kinase activity through ligand binding. ErbB
family receptor activation will initiate a number of downstream signal-
ing pathways, such as mitogen-activated protein kinase (MAPK), acti-
vator of transcription (STAT), the modulation of calcium channels, and
so on. These downstream signaling activations modulate cell prolifera-
tion, survival, adhesion, migration and differentiation [6–9]. Except for
ErbB4, the expression and constitutive activation of other ErbB family
members can be found in human tumors of epithelial origin, which
leads to aggressive tumor behavior, such as cancer initiation, tumor pro-
gression, metastasis and chemo-resistance [10–13].
ErbB family members are often over-expressed, ampliﬁed or mu-
tated in many forms of cancer, making them important therapeutic
targets [14]. Drugs such as cetuximab, panitumumab, erlotinib,
geﬁtinib are used to inhibit ErbB1/EGFR which is overexpressed in
many cancers [15]. It has recently been shown that acquired resis-
tance to cetuximab and geﬁtinib can be linked to hyperactivity of
ErbB3 [16]. ErbB2/neu/HER2 is often overexpressed in breast cancer.
The drug trastuzumab (Herceptin) targets this receptor. Only one-
third of the women respond to trastuzumab, and recently it was not
known what causes the resistance to trastuzumab.
Gillies et al. [17] showed thatmicroenvironmental forces, speciﬁcal-
ly hypoxia, acidosis and reactive oxygen species, are not only highly se-
lective, but are also able to induce genetic instability. Under long-term
hypoxia and nature selection pressure, EGFR will show adaptive
changes, such as increasing expression [18], or the production of more
adaptive genes through geneduplication. Although biochemical and ge-
netic studies in humans and other species have led to important discov-
eries in understanding the function of the ErbB family, some members
of this family have proven biological roles in a limited number of spe-
cies. Detecting positive Darwinian selection in a protein, or indeed in a
lineage of a phylogeny, indicates that there is a selective advantage in
changing the amino acid sequence. These positive selection sites are
essential for our understanding of functionally important residues in a
protein sequence and protein functional shift. Accordingly, this study
may provide a new perspective to solve the problem of acquired resis-
tance or offer new therapeutic possibilities [2]. In addition, the role of
gene duplication, natural selection and functional diversiﬁcation in
the evolution of the ErbB family is unknown. Therefore, phylogenetic
analysis, structural evolution and function divergence of ErbB family
in vertebrates from a comprehensive comparative genome study are
essential.
In this study, we take advantage of the exponential increase of pub-
licly available genomic sequences to present the functional evolution of
the ErbB family. In addition, the functional divergence of amino acids
and nucleotides of different species, covering all vertebrates in the data-
bases, was analyzed. The aim of this study was to clarify the evolution-
ary mechanisms operating in the retention of ErbB genes and assess the
changes in selection pressures following duplication. The sites under
positive Darwinian selection were also determined. Finally, in order to
clarify the position of the positively selected sites and divergence
sites, we tried to map the positively selected sites and divergence sites
to the sequence alignment and the 3D structure model.
2. Materials and methods
2.1. Sequence data collection
The amino acid sequences and cDNA sequences of EGFR genes were
downloaded from the UniProt (http://www.uniprot.org/) proteindatabase, NCBI's GenBank (http://www.ncbi.nlm.nih.gov) and the
Ensembl database (http://asia.ensembl.org/index.html). Blast and
PSI-BLAST searches were conducted against the non-redundant data-
base of vertebrate genomes at UniProt and NCBI, respectively, using
the human amino acid sequences of EGFR, ErbB2, ErbB3, ErbB4
(gi:1956, gi: 2064, gi:2065, gi:2066, respectively) as queries. Blast
searches were performed with the following criteria: E value b 1e-24
and only full length coding sequences were included. Sequences with
identity higher than 95% were used in Jalview 2.3 [19].
2.2. Sequence alignment
Amino acid sequences of EGFR family members were aligned by the
EBI web tool MUSCLE [20] (http://www.ebi.ac.uk/Tools/msa/muscle/)
with the default parameters, then poorly aligned positions, gap posi-
tions and highly divergent regions from the alignmentwere completely
excluded for further analyses. We generated the rearranged cDNA se-
quences according to the new amino acid alignment. Because the tool
PAL2NAL can construct multiple codon alignments from matching
amino acid sequences, we subsequently transformed the amino acid
alignment into an aligned CDS fasta ﬁle using the EMBL web tool
PAL2NAL [21] (http://www.bork.embl.de/pal2nal/). The ﬁnal data set
included a total of sixty-two sequences from twenty seven species.
MEGA4.0 [22] was used to convert the nucleotide alignment into
nexus format for phylogenetic analyses.
2.3. Phylogenetic analysis
We carried out phylogenetic inference to the full alignment of
sixty-two sequences. The Akaike Information Criterion (AIC) in PAUP*
version 4.0 [23] was applied to evaluate the most appropriate model
of amino acid substitution for tree-building analyses. Maximum likeli-
hood (ML) optimizations and distance methods were evaluated by the
PhyML program [24] in PAUP* version 4.0. The model of sequence evo-
lution (GTR + I + G) was selected using Modeltest version 3.7 [25].
Then, according to the best-ﬁt model predicted, tree reconstructions
were done using the Bayesian method from the DNA alignment with
the MrBayes version 3.1.2 software [26,27]. The parameters for tree
generating were as follows: 10 million generations with sampling
every 10 thousand generations, with four chains (three heated, one
cold). After completing MrBayes analysis, the ﬁrst 250,000 generations
(25 trees) were discarded from every run, and the remaining treeswere
concatenated. The remaining 199,975 trees were used to compute the
ﬁnal (consensus) tree, and to determine the posterior probabilities at
the different nodes [28].
2.4. Estimating the pattern of nucleotide substitution and positive-
selection sites
Selective pressure of ErbB family genes was examined from CODEML
in the PAML package version 4.4 [29], three codon-based likelihood
methods were run: branch models, site models and branch-site models.
In these analyses, maximum likelihood estimates of the selection
pressure were based on the ratio dN/dS (or ω), which are the non-
synonymous (dN) and synonymous substitution rates (dS) that vary
across codons, and the probability of each codon being under positive se-
lection was estimated. According to the positive selection, if ω > 1, the
positive selection sites may occur in very short episodes or on only a
few sites during the evolution of duplicated genes; the alignments
resulted from PAL2NAL. The parameter estimates (ω) and likelihood
scores recommended by Wong et al. [30] and Anisimova et al. [31]
were calculated for three pairs of models: the models including M0
(one ratio) versus M3 (discrete), M1a (nearly neutral) versus M2a (pos-
itive selection) andM7 (beta) versusM8 (beta + ω); thesewere used in
our study. The likelihood ratio test (LRT) was used to compare the ﬁt to
the data of two nested models, assuming that twice the log likelihood
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a number of degrees of freedom equal to the difference in the number of
free parameters [32]. naive empirical Bayes (NEB) method and Bayes
empirical Bayes (BEB) method [33] implemented in PAML4 were used
to identify sites under positive selection or relaxed from purifying selec-
tion in the foreground group with signiﬁcant LRTs. Each branch group
was labeled as a foreground group in turn as well. The technique route
can be seen in Fig. 1.2.5. Testing functional divergence and structure analysis
Type I (θI) and Type II (θII) functional divergence coefﬁcients were
estimated by the Diverge 2.0 software in order to study the functional
divergence and structural differences after the gene duplication [34]
among the EGFR family member proteins. Type I refers to shifts in
the evolutionary rate pattern after the emergence of a new phyloge-
netic cluster, which is indicative of changes in functional constrains,
while Type II refers to amino acid replacements that are completely
ﬁxed between duplicates, resulting in cluster-speciﬁc alterations of
amino acid physiochemical properties.2.6. The positive selection in protein sequence and structure analysis
The protein sequence alignment of the EGFR family (Fig. 2) was
done with ClustalW and displayed through GeneDoc (http://www.
nrbsc.org/gfx/genedoc/); the functional area in the ﬁgure is com-
posed with positive selection sites, ATP binding sites, dimer interface
regions, activation loop regions, substrate recognition sites and trans-
membrane regions. The positive selection sites were marked
according to the experimental results; the transmembrane region
prediction was done with TMHMM v2.0 [35] and the other predic-
tions were from the NCBI database. The genes predicted to be subject
to positive selection were used to search for homologous sequences
in the PDB database of protein structures by using Blastp (http://
www.rcsb.org/pdb/home/home.do) [36,37]. To structure the manipu-
lations and highlighting the relevant amino acid replacements identi-
ﬁed in the evolutionary analyses, we used the PYMOL software
version1.5 (http://www.pymol.org/).Fig. 1. Technical routes about positive analysis of th3. Results
3.1. Origins of the EGFR family during vertebrate evolution
We found similar protein and cDNA sequences to human EGFR
family genes in 26 other vertebrate species: Mus musculus, Rattus
norvegicus, Macaca mulatta, Sus scrofa, Monodelphis domestica, Canis
familiaris, Gallus gallus, Danio rerio, Xenopus laevis, etc. After the exclu-
sion of partial and unﬁnished cDNA sequences, we ﬁnally downloaded
62 EGFR family genes from the above 27 species.
To investigate the phylogenetic relationship of vertebrate EGFR
family genes, Bayesian methods were applied in phylogenetic infer-
ence analyses based on codon alignment and the history of their
evolutionary inference. In addition, we used the Bayesian posterior
probability (PP) methods to evaluate clade support. The consensus
phylogeny obtained for EGFR family gene sequences is shown in
Fig. 3. The phylogeny showed that the EGFR family in vertebrates con-
sists of four distinct branch clusters, all with high PP supportive
values, indicating that the formation of the paralogous lineages oc-
curred before the divergence of individual species [38], and the
EGFR orthologs (EGFR, ErbB2, ErbB3 and ErbB4) from Drosophila
virilis, Drosophila melanogaster, Drosophila simulans, Aedes aegypti,
Gryllus bimaculatus, Lymnaea stagnalis, Ciona intestinalis, Acromyrmex
echinatior, Harpegnathos saltator and Camponotus ﬂoridanus were
just located as an outgroup of their assigned lineages. From Fig. 3,
we inferred that two major duplications had occurred early in the
vertebrate lineages. The ﬁrst duplication led to the emergence of
two lineages which evolved into EGFR and ErbB2, and the second du-
plication, also early in vertebrate evolution, resulted in ErbB3 and
ErbB4.
3.2. Positively selected sites in the EGFR family and putative biological
signiﬁcance
We performed a site-based analysis with PAML package version
4.4 (Table 1) to detect the selective pressure on the EGFR family in
vertebrates. After the removal of gaps, 315 sites were analyzed
using the CODEML program. Except for M1a vs. M2a, the LRTs were
signiﬁcant in comparisons (M0 vs. M3, M7 vs. M8), indicating that
M3 and M8 ﬁt the data better; however, we were unable to detecte site, branch and branch-site for ErbB family.
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Fig. 2. Protein structure of EGFR family. The model of human EGFR protein was based on homology modeling. These four human sequences include positive selection sites, ATP
binding sites, dimer interface region, activation loop region, substrate recognition sites and transmembrane region.
321Y. Liu et al. / Genomics 101 (2013) 318–325any selected sites in M3. 23.23% of sites underwent positive selection
according to M8 models. Two sites (637P, 638T) were detected as
positively selected sites with a p-value of at least 99%, and two
more sites (639N, 1060I) were detected as potential targets of posi-
tive selection with a p-value of at least 95%.
Because positive selection might happen only in speciﬁc stages of
evolution or in speciﬁc branches, positive selection affects only some
branches. We used a branch-speciﬁc model to detect the positive
selection (Table 2). The free ratio model was signiﬁcantly higher
than the one ratio model (Δln L = 1369.78, p b 0.01, df = 119), indi-
cating heterogeneous selection among branches. Two ratio models
were used according to these ten branches, and the results showed
that three models (Ta, Tc and Td) were not signiﬁcantly different.
The LRT of models Tg and Ti were signiﬁcantly higher than the one
ratio model, but they did not have ω > 1. Five models (Tb, Te, Tf, Th
and Tj) had both statistical signiﬁcance and ω > 1, so branch site
models were used to search for amino acid sites that underwent pos-
itive selection in branches Tb, Te, Tf, Th and Tj.
According to the LRT of branch site models, comparisons of BSb1
vs. BSb0-ﬁx (Δln L = 4.16, p b 0.05, df = 1) and BSf1 vs. BSf0-ﬁx(Δln L = 9.22, p b 0.01, df = 1) were signiﬁcantly different. BEB
methods were used to evaluate the a posteriori probability of positive
selection sites. There was one amino acid site (47H) in branch f with
an a posteriori probability of >0.5 for BSb1 vs. BSb0-ﬁx. Interestingly,
9 amino acid sites in branch f had a posteriori probabilities of >0.5 by
BEB, and the amino acid site at position 47H had an a posteriori prob-
ability of 0.966 by BEB methods, which was signiﬁcant at the 5% level.
Thus, a crucial amino acid site (47H) was considered to undergo pos-
itive selection. The detail can be seen in Table 3.
3.3. Functional divergence
Gene duplication-speciﬁc changes in the substitution ratesmight re-
ﬂect the difference in evolutionary rates at amino acid sites [38]. This
type of gene duplication-speciﬁc changes in the substitution are called
Type I functional divergence. The coefﬁcient of Type I functional diver-
gence between duplicate genes, θML, is deﬁned as the probability of
functional divergence [37]. In our study, except for EGFR vs. ErbB2
(p = 0.087) and EGFR vs. ErbB4 (p = 0.051), signiﬁcant evidence be-
tween different gene clusters were found in the comparisons of Type I
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Fig. 3. Phylogenetic relationships of DNA sequences within the EGFR family. Phylogenetic tree based on the nucleotide sequence data. The numbers indicate the Bayesian proba-
bilities for each phylogenetic clade. Shaded boxes denote the four lineages and one outgroup. The scale bars represent codon substitutions per site.
322 Y. Liu et al. / Genomics 101 (2013) 318–325functional divergence (Theta ML = 0.227 ~ 0.801, p b 0.01; Table 4.).
The results showed that therewere some amino acid sites with discrep-
ancies in their evolutionary rate between these paralogous pairs.
Type II sites are ﬁxed in both groups; however, their biochemical
properties vary between sister clusters, denoting these residues charge
for the functional differences between these groups. Recently, Ono et al.
[39] developed a method to test for Type II functional divergence. The
analyzed results showed that there was no clear evidence for Type II
functional divergence on the whole (p > 0.05). However, we performed
a further study to conﬁrm whether there was any potential site for Type
II functional divergence. If the a posteriori ratio test value of an amino
acid site was more than 4, it was considered to be a potential Type II
site [40]. Thus, 104 potential Type II sites were detected in all pairs.
3.4. Protein structure
Because the structure of EGFR family members is highly conserved,
particularly within families, the model of human EGFR proteins was
based on homology modeling (Fig. 2). The model was composed ofthirteen ATP binding sites, ﬁve dimer interface regions, one activation
loop region, one substrate recognition site and two transmembrane re-
gions. To throw some insight into the roles that positive selection and
functional prediction might have, we mapped these sites onto the
model as well as along the sequence alignment. The results showed
that the distribution of these sites is largely disordered but they are con-
centrated in some parts.
3.5. Spatial distributions of possible selected EGFR sites on three-
dimensional structure
Because of the evidence for possible positive selection on EGFR, we
predicted positively selected sites using a BEB method. Five sites were
identiﬁed as positively selected at a BEB posterior probability threshold
of 95%. In order to plot positive selected sites onto a human (EGFR)
three-dimensional model, we ﬁrst built an energy-minimized model
using a homology modeling approach [41]. The PDB entry with the
highest sequence similarity identiﬁed in the PSI-BLAST corresponds to
the human EGFR (PDB: 1nql) [42]. We have mapped three positively
Table 1
Parameter estimates and likelihood scores of EGFR family for site models in PAML.
Model np Estimates of parameters lnL LRT pairs df 2ΔlnL p Positively selected
sites (BEB)
Site model
M0:one ratio 122 ω = 0.09935 −137156.09 M0/M3 4 9554.38 0.0000
M3:discrete 126 p0 = 0.28447, p1 = 0.38340, p2 = 0.33213,
ω0 = 0.01401, ω1 = 0.08176, ω2 = 0.27793
−132378.90
M1a:neutral 123 p0 = 0.76182, p1 = 0.23818, ω0 = 0.09269,
ω1 = 1.00000
−135374.98 M1a/M2a 2 0.00 1.0000
M2a:selection 125 p0 = 0.76182, p1 = 0.00000, p2 = 0.23818,
ω0 = 0.09269, ω1 = 1.00000, ω2 = 1.00000
−135374.98
M7:beta 123 p = 0.66485, q = 3.93861 −132108.16 M7/M8 2 15914.60 0.0000 637P**, 638 T**,
639 N*, 1060I*M8:beta&ω 125 p0 = 0.99999, p = 0.23229, q = 1.99686,
p1 = 0.00001, ω = 1.54937
−140065.46
Selection analysis by site models was performed using CODEML implemented in PAML. np: number of free parameters. lnL: loglikelihood. LRT: likelihood ratio test. df: degrees of
freedom. 2ΔlnL: twice the log-likelihood difference of the models compared. The signiﬁcant tests at 5% cut off are labeled with* and at 1% cut off are labeled with**. Bold: Pb0.05.
323Y. Liu et al. / Genomics 101 (2013) 318–325selected sites (47H, 637P, 638T) onto the surface of the 3D structure
(Fig. 4), excluding two positively selected sites (639N, 1060I), because
the crystal structures of EGFR proteins are mainly focused on the extra-
cellular domain. Whereas the positive selected sites were mainly locat-
ed in the N-terminal and non-functional regions of EGFR, it was also
indicated that EGFR underwent strong constraint in the functional do-
main as well.
4. Discussion
Conceptualizing cancer in an evolutionary context promises to
transform our understanding of the condition and offers new thera-
peutic possibilities [43]. The four members of the ErbB protein family
are capable of forming homodimers, heterodimers, and possibly
higher-order oligomers upon activation by a subset of potential
growth factor ligands. However, their biological roles in many species
are not clear. As the accumulation of gene sequences in the database
occurs, it is feasible to explore evolutionary relationships and the
functional diversity of the ErbB family. In this study, 62 sequences
were used for phylogenetic reconstruction with Bayesian inference.
Phylogenetic analyses showed the ErbB family formation of the
paralogous lineages occurred before the divergence of individual spe-
cies. We inferred that two major duplications had occurred early in
the vertebrate lineages. The ﬁrst duplication led to the emergence of
two lineages, which evolved into EGFR and ErbB2, and the second du-
plication, also early in vertebrate evolution, resulted in ErbB3 and
ErbB4. This result was similar with the functional divergence analysis.
The results of phylogenetic analyses clearly constructed ErbB classiﬁ-
cation, which may be related to their functional divergence. TwoTable 2
Parameter estimates and likelihood scores of EGFR family for branch models in PAML.
Model np Estimates of parameters lnL
Fr: free ratios 241 −136471.20
Tx: two ratios
Ta 123 ω0 = 0.0994, ωa = 999.0000 −137154.76
Tb 123 ω0 = 0.0999, ωb = 999.0000 −137149.94
Tc 123 ω0 = 0.0996, ωc = 69.0334 −137155.37
Td 123 ω0 = 0.0989, ωd = 0.1370 −137155.21
Te 123 ω0 = 0.0999, ωe = 999.0000 −137150.88
Tf 123 ω0 = 0.1000, ωf = 999.0000 −137148.39
Tg 123 ω0 = 0.0989, ωg = 0.0009 −137151.66
Th 123 ω0 = 0.0985, ωh = 1.1529 −137137.09
Ti 123 ω0 = 0.0992, ωi = 0.4132 −137153.29
Tj 123 ω0 = 0.0986, ωj = 999.0000 −137151.64
Selection analysis by branch models was performed using CODEML implemented in PAML. n
freedom. 2ΔlnL: twice the log-likelihood difference of the models compared. Bold: Pb0.05,main ligand classes have to date been identiﬁed for ErbB family. Sig-
naling diversity depends both on the presence of speciﬁc receptors
and the characteristics of individual ligands. Epidermal growth factor
receptors differ in their ligand speciﬁcities. EGFR and HER2 classically
couple to Ras-Raf-MEK-mitogen-activated protein kinase (MAPK)-
dependent pathway, whereas HER3 is a potent activator of phos-
phatidylinositol 3-kinase (PI3-K)-Akt [44].
Positive selection is the retention and spread of advantageous mu-
tations throughout a population and has long been considered synon-
ymous with protein functional shift [45]. Vamathevan et al. [46]
found that positively selected genes are signiﬁcantly more likely to
interact with other positively selected genes than with genes evolv-
ing under neutral evolution or purifying selection. In addition, selec-
tion events on coding sequences may also have effects on gene
expression regulation. Along with lineage heterogeneity, different ω
in all sites would occur. In our study, site models, branch models
and branch-site models were used to detect positive selection along
pre-speciﬁed groups, separately, because one category of ω from
site model analysis did not ﬁt data well enough to describe the vari-
ability in selection pressure across amino acid sites. In addition, the
results of branch models showed that the ω ratios vary among clades.
Branch-site models were applied to evaluate of some sites along spe-
ciﬁc clades of the ErbB phylogeny.
Tyrosine kinases of the EGFR family are frequently mutated in
human cancers. Mutations in the tyrosine kinase domain of EGFR
(encoded by exons 18–24) have mostly been found in lung cancers
[47–51]. Therewere seven positive selections detected in the ErbB fam-
ily: three positive selection sites (30V, 47H, 51L)were located in exon 2,
two sites (637P, 638T) were located in exon 18, one site (639N) wasLRT pairs df 2ΔlnL p Positively selected
sites (BEB)
M0/Fr 119 1369.78 0.0000
M0/Ta 1 2.67 0.1025
M0/Tb 1 12.31 0.0005
M0/Tc 1 1.44 0.2301
M0/Td 1 1.75 0.1853
M0/Te 1 10.41 0.0013
M0/Tf 1 15.40 0.0001
M0/Tg 1 8.86 0.0029
M0/Th 1 38.00 0.0000
M0/Ti 1 5.61 0.0179
M0/Tj 1 8.90 0.0029
p: number of free parameters. lnL: loglikelihood. LRT: likelihood ratio test. df: degrees of
ω>1.
Table 3
Parameter estimates and likelihood scores of EGFR family for branch-site models in PAML.
Model np Estimates of parameters lnL LRT pairs df 2ΔlnL p Positively selected
sites (BEB)
BSb1 125 p0 = 0.96286, p1 = 0.00923, p2a = 0.02765, p2b = 0.00027,
ω0 = 0.02994, ω1 = 1.00000, b:ω2a = 0.02994, ω2b = 1.00000,
f:ω2a = 999.00000, ω2b = 999.00000
−8717.48 BSb1/BSb0-ﬁx 1 4.16 0.0414
BSb0-ﬁx 124 p0 = 0.94090, p1 = 0.00902, p2a = 0.04960, p2b = 0.00048,
ω0 = 0.0.02964, ω1 = 1.00000, b:ω2a = 0.02964, ω2b = 1.00000,
f:ω2a = 1.00000, ω2b = 1.00000
−8719.56
BSe1 125 p0 = 0.93756, p1 = 0.00899, p2a = 0.05294, p2b = 0.00051,
w0 = 0.02993, ω1 = 1.00000, b:ω2a = 0.02993, ω2b = 1.00000,
f:ω2a = 10.05218, ω2b = 10.05218
−8715.92 BSe1/BSe0-ﬁx 1 2.72 0.0991 30V* 51L*
BSe0-ﬁx 124 p0 = 0.91778, p1 = 0.00880, p2a = 0.07272, p2b = 0.00070,
w0 = 0.02957, ω1 = 1.00000, b:ω2a = 0.02957, ω2b = 1.00000,
f:ω2a = 1.00000, ω2b = 1.00000
−8717.28
BSf1 125 p0 = 0.89176, p1 = 0.00856, p2a = 0.09873, p2b = 0.00095,
ω0 = 0.03176, ω1 = 1.00000, b:ω2a = 0.03176, ω2b = 1.00000,
f:ω2a = 999.00000, ω2b = 999.00000
−8709.93 BSf1/BSf0-ﬁx 1 9.22 0.0024 47 H*
BSf0-ﬁx 124 p0 = 0.84177, p1 = 0.00808, p2a = 0.14873, p2b = 0.00143,
ω0 = 0.03075, ω1 = 1.00000, b:ω2a = 0.03075, ω2b = 1.00000,
f:ω2a = 1.00000, ω2b = 1.00000
−8714.54
BSh1 125 p0 = 0.96441, p1 = 0.00925, p2a = 0.02609, p2b = 0.00025,
ω0 = 0.02954, ω1 = 1.00000, b:ω2a = 0.02954, ω2b = 1.00000,
f:ω2a = 188.46766, ω2b = 188.46766
−8717.42 BSh1/BSh0-ﬁx 1 3.16 0.0755 47H*
BSh0-ﬁx 124 p0 = 0.95198, p1 = 0.00913, p2a = 0.03852, p2b = 0.00037,
ω0 = 0.02939, ω1 = 1.00000, b:ω2a = 0.02939, ω2b = 1.00000,
f:ω2a = 1.00000, ω2b = 1.00000
−8719.00
BSj1 125 p0 = 0.05879, p1 = 0.00056, p2a = 0.93172, p2b = 0.00893,
w0 = 0.02989, w1 = 1.00000, b:w2a = 0.02989, w2b = 1.00000,
f:w2a = 1.00000, w2b = 1.00000
−8721.35 BSj1/BSj0-ﬁx 1 0.00 1.0000
BSj0-ﬁx 124 p0 = 0.74167, p1 = 0.00711, p2a = 0.24883, p2b = 0.00239,
ω0 = 0.02989, ω1 = 1.00000, b:ω2a = 0.02989, ω2b = 1.00000,
f:ω2a = 1.00000, ω2b = 1.00000
−8721.35
Selection analysis by branch-site models was performed using CODEML implemented in PAML. BS: branch-site. The signiﬁcant tests at 5% cut-off are labeled with * and at 1% cut-off
are labeled with **. Bold: Pb0.05.
47H 
324 Y. Liu et al. / Genomics 101 (2013) 318–325located in exon 19 and one site (1060I) was located in exon 29; howev-
er, our research still has some discrepancies with the present experi-
mental study. After all, the results indicate that ErbB family may have
other function sites which may offer new therapeutic possibilities.
After major evolutionary events such as gene duplication or speci-
ation, speciﬁc sites in proteins have the potential to undergo two dis-
tinct types of divergences (e.g., divergence among the different
groups within the large and small subunits), which can be assigned
as Type-I and Type-II divergences. Type I divergence results in
site-speciﬁc rate shifts after gene duplication, and Type II divergence
results in site-speciﬁc properties (hydrophobicity and hydrophilici-
ty). The process of gene duplication and functional divergence is
an important originator of molecular novelty and has produced aTable 4
Maximum likelihood estimates of the coefﬁcient of functional divergence (θ) from
pairwise comparisons between EGFR groups.
Type I
Comparison Theta ML Alpha ML SE theta LRT theta Sig.
EGFR Vs ErbB2 0.227 0.297 0.133 2.928 0.087
EGFR Vs ErbB3 0.655 0.54 0.159 17.02 0.000
EGFR Vs ErbB4 0.738 0.282 0.248 8.877 0.003
ErbB2 Vs ErbB3 0.726 0.66 0.186 15.243 0.000
ErbB2 Vs ErbB4 0.801 0.323 0.282 8.079 0.004
ErbB3 Vs ErbB4 0.719 0.944 0.369 3.796 0.051
Type II
Comparison Alpha ML Theta-II Theta SE
EGFR Vs ErbB2 0.297 0.041 0.079
EGFR Vs ErbB3 0.540 0.413 0.095
EGFR Vs ErbB4 0.282 0.147 0.074
ErbB2 Vs ErbB3 0.660 0.484 0.090
ErbB2 Vs ErbB4 0.323 0.224 0.071
ErbB3 Vs ErbB4 0.944 0.131 0.117number of present protein families [34,39,40]. Therefore, identifying
the functional diversity of amino acid sites from sequence analysis
is desirable. In this research, we performed Type I functional diver-
gence analysis, and found signiﬁcant Type I divergence among ErbB
family. The comparison between group 1 (ErbB1, ErbB2) and group
2 (ErbB3, ErbB4) showed high values for θ (0.655–0.801), and the p
values were all less than 0.01. However, the value between ErbB1
and ErbB2 was the lowest (θ = 0.227), in contrast to ErbB3 and
ErbB4 (θ = 0.719). These results suggest that functional divergence637P 
638T 
Fig. 4. Partial positive selection sites acting on the modeled structure of human EGFR
(PDB accession number 1nql).
325Y. Liu et al. / Genomics 101 (2013) 318–325was considerable between the groups of ErbB1 and ErbB2 and groups
of ErbB3 and ErbB4.
To further characterize the relationship of functional divergence
and site-speciﬁc evolution of amino acids, Type I and Type II function-
al divergences and some potential amino acid sites related to positive
selection were selected and mapped to the sequence alignment and
the 3D structural model. The results showed that the functional diver-
gence of the 1060I site was also found in the site-speciﬁc evolution of
amino acids, which suggests that the 1060I site-speciﬁc evolution was
closely related to functional divergence in the ErbB family.
5. Conclusion
Studying the evolution of functional and biomedical disease differ-
ences between species is an important way to gain insight into their
molecular cause. ErbB family receptor activation will initiate a num-
ber of downstream signaling pathways which modulate cell prolifer-
ation, survival, adhesion, migration and differentiation. However, the
natural selection and functional divergence of the ErbB family were
not clear. In this study, the phylogenetic relationship of 27 vertebrate
species was built. An evolutional phylogeny of 27 vertebrates was
presented in our study; the tree showed that two major duplications
had occurred early in the vertebrate lineages. In the process of func-
tional differentiation evolving through gene duplication, relaxed se-
lection may play an important part, except for seven sites (30V,
47H, 51L, 637P, 638T, 639N, 1060I) that had evolved by positive
selection. There was also one common site (1060I) showing positive
selection and functional divergence. This study may provide a new
perspective to solve the problem of acquired resistance or offer new
therapeutic possibilities.
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